Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Somatostatinoma 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Fallopian Tube Neoplasms 1

Interventions

Temozolomide 4Capecitabine 4Bevacizumab 3Leucovorin 2Fluorouracil 2Everolimus 2temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1motesanib diphosphate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1batifiban 1aflibercept 1Sunitinib 1Sorafenib 1Sirolimus 1Panobinostat 1Oxaliplatin 1Octreotide 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Fentanyl 1Etoposide 1Doxorubicin 1Disulfides 1Cytidine Triphosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Somatostatinoma × Cytidine Triphosphate × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡